Drug discovery today operates with stunning inefficiency - billions of dollars invested, decades of work expended, yet over 90% of candidates fail in clinical trials because our understanding of human biology remains fundamentally incomplete. insitro exists to fix this. By generating the world's largest integrated multi-modal corpus of human and cellular data, we've built the Virtual Human™ - a genetically anchored causal AI engine that reveals how disease begins, progresses, and can be resolved. Our platform precisely identifies causal genetic drivers and deploys our TherML™ AI platform to design optimal medicines, advancing a broad pipeline of therapeutics for neuroscience and metabolic diseases.
This industrialized architecture creates a self-learning loop: with every biology we onboard, our predictive models grow smarter, accelerating discovery across scales of biology. We've built a unique culture where life scientists, data scientists, engineers, and drug hunters work together to identify the most important questions, design and scale experiments, build models, and analyze the results. Our differences enhance our strengths, and our collective expertise comes together to generate scientific breakthroughs that bring better drugs faster to the patients who can benefit most.